Ardelyx (ARDX) closed at $3.01 on November 10, 2026, up 2.7% from the previous close, on volume of 5,267,449 shares (30-day average 4,674,659).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Calendar Call Spread | 15-Jan : 16-Apr-27 2 C | 324 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Tue, 10-Nov 11:06 AM ET)
Globe Newswire (Tue, 10-Nov 9:00 AM ET)
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Globe Newswire (Tue, 10-Nov 7:30 AM ET)
TipRanks (Tue, 10-Nov 6:26 AM ET)
Globe Newswire (Mon, 9-Nov 9:14 PM ET)
Newsfile (Mon, 9-Nov 7:49 PM ET)
Globe Newswire (Mon, 9-Nov 10:09 AM ET)
Newsfile (Mon, 9-Nov 6:20 AM ET)
Newsfile (Sun, 8-Nov 7:44 PM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of November 10, 2026, ARDX stock price climbed to $3.01 with 5,267,449 million shares trading.
ARDX has a beta of 0.94, meaning it tends to be less sensitive to market movements. ARDX has a correlation of 0.04 to the broad based SPY ETF.
ARDX has a market cap of $777.14 million. This is considered a Small Cap stock.
Last quarter Ardelyx reported $126 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.02.
In the last 3 years, ARDX traded as high as $10.13 and as low as $2.80.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, PBE.
ARDX has underperformed the market in the last year with a return of -46.2%, while the SPY ETF gained +12.9%. In the last 3 month period, ARDX fell short of the market, returning -24.8%, while SPY returned -2.8%. However, in the most recent 2 weeks ARDX has outperformed the stock market by returning +0.3%, while SPY returned -2.0%.
ARDX support price is $2.84 and resistance is $3.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.
